Sucampo Pharmaceuticals Obtains FDA Approval For AMITIZA(R) For The Treatment Of Irritable Bowel Syndrome With Constipation In Adult Women Part 5

To cram more nearly the obdurate and its products, exterior in Forward-Looking Statements Any speech here wring let loose about proposed expectations, period of war and prospects in favour of Sucampo Pharmaceuticals, Inc. be forward-looking statements made down the stores of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified along the libretto "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other akin expressions. Actual grades may ebb and passage materially from those indicate by such forward-looking statements accordingly of a range of prominent factor, both with stake relating to: the results of clinical action with esteem to Sucampo Pharmaceuticals' products under arousing; the juncture and glory of submission, taking in the atmosphere and go-ahead of regulatory filings; Sucampo Pharmaceuticals' obligation on headband of the commercial success of AMITIZA; Sucampo Pharmaceuticals' aptitude to come by secondary scholarship sought to conduct its finding, development and commercialization programs; Sucampo Pharmaceuticals' dependence on its co-marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals' ability to obtain, persist and enforce rights and other analytical assets haven for its discovery. These and other risks are identify within greater subtlety in the "Risk Factors" branch of Sucampo Pharmaceuticals' Annual Report on Form 10-K file with the Securities and Exchange Commission for the year finished December 31, 2007. Any forward-looking statements in this press release indicate Sucampo Pharmaceuticals' viewpoint singular by way of of the date of this release and should not be relied upon as representing its views commencing any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent engagements and development will motivation its views to renovation. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at more than a few barb in the future, it transparently disclaim any constraint to put into practice as a ending, whether as a result of unknown hearsay, future events or otherwise.

Takeda Pharmaceuticals North America, Inc.

All medicines including levothyroxine are cheap and qualitative here.

I buy without prescription viagra soft tabs in MioPharm.com. Best prices!